MicroRNA

Aspira Women’s Health Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
Thursday, March 28, 2024
Research, Ovarian cancer, California Department, Conference call, Conference, Development, MicroRNA, Artificiality, Patient, Travel, Cancer, Information technology, AUP, Society, Gynaecology, AACR, Poster, Medicare, Marketing, CMS, Human resources, Federal, Medi-Cal, Cryptocurrency

AUSTIN, Texas, March 28, 2024 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira” or the “Company”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, today reported its financial results for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Aspira will be reimbursed at a rate of $897 for all OvaWatch and Ova1 tests processed for Medicare patients meeting applicable coverage requirements.
  • Aspira will be reimbursed at a rate of $897 for all Ova1Plus tests processed for Medi-Cal patients meeting applicable coverage requirements.
  • Gross profit margin was 57.5% for the year ended December 31, 2023, compared to 52.8% for the year ended December 31, 2022.
  • Subsequent to the end of the quarter, Aspira raised $5.5 million in gross proceeds in a registered direct offering and concurrent private placement.

City of Hope Scientists Present Leading-Edge Research at American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Monday, April 8, 2024
Science, Biotechnology, Research, Oncology, Health, Health Technology, Genetics, Clinical Trials, Breast cancer, Survival, Immunotherapy, Health equity, Patient, Lung, City, National Cancer Institute, AGAF, Breast, MicroRNA, Pancreatic cancer, Lymphocyte, Clinical trial, Neoplasm, Therapy, Cancer, Exosome, Plasma, Colorectal cancer, Risk, Experiment, DNA, Virus, Translational Genomics Research Institute, Memory, Treatment, Cholangiocarcinoma, Pathology, Liquid biopsy, Microbiome, Recurrence, Irell & Manella, Disease, Intelligence, Molecular diagnostics, Overalls, AACR, TILS, Pancreas, Prognosis, Beckman Research Institute, Biomarker, Abdomen, Biology, Abstract, Bangladesh Technical Education Board, Data, Blood, Medical imaging

“City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.

Key Points: 
  • “City of Hope’s research presented at AACR’s conference this year reinforces our focus on early detection, smarter and more precise treatments, and achieving health equity.
  • “Cancer is complex and the breadth and diversity of research this year further underscores the talent, scientific rigor and curiosity at City of Hope,” Van den Brink added.
  • But those diagnosed when the cancer is contained to the pancreas have a 44.3% relative survival rate after five years.
  • Scientists with Translational Genomics Research Institute, part of City of Hope, also contributed to the study.

National Geographic Magazine Showcases NanoString’s Spatial Biology Technology to Examine Cell Death in Alzheimer’s Disease

Retrieved on: 
Wednesday, March 27, 2024
Seniors, Nanotechnology, Research, Software, Medical Devices, Hardware, Consumer, Genetics, Professional Services, Science, Technology, Clinical Trials, Publishing, Data Analytics, Biotechnology, Health, Communications, Health Technology, National Geographic, MicroRNA, Brain, Gene, Myenteric plexus, Gene expression, NanoString Technologies, Cell, Disease, Memory, Alzheimer's disease, Tau, Risk, Hippocampus, Inflammation, Patient, RNA, News, Federal republic, Protein, Biology, Proteomics, Publication, OTC, Ecosystem, Multimedia, SMI, Ageing

When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.

Key Points: 
  • When blue, magenta, and green all appear in a cell, especially a large cell, that's evidence it is a zombie cell.
  • (Graphic: NanoString)
    A special-interest magazine from National Geographic called Anti-Inflammation, available on newsstands this week, spotlights the role of inflammation on health and disease.
  • NanoString Technologies, a leader in spatial biology, offers an ecosystem of innovative discovery and translational research solutions, empowering our customers to map the universe of biology.
  • The AtoMx™ Spatial Informatics Platform is a cloud-based informatics solution with advanced analytics and global collaboration capabilities, enabling powerful spatial biology insights anytime, anywhere.

Coeptis Therapeutics Congratulates Alexander Deiters, Professor at the University of Pittsburgh, on Receiving the 2024 Chancellor's Distinguished Research Award

Retrieved on: 
Tuesday, April 2, 2024
Health, Interdisciplinarity, Enzyme, Cell, Neoplasm, Research, Science, Cancer, University, Biology, MicroRNA, Chemistry, Therapy, NK, Pharmaceutical industry

WEXFORD, Pa., April 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, is pleased to acknowledge and congratulate Professor Alexander Deiters, on receiving the University of Pittsburgh's 2024 Chancellor's Distinguished Research Award.

Key Points: 
  • WEXFORD, Pa., April 2, 2024 /PRNewswire/ -- Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) ("Coeptis" or "the Company"), a biopharmaceutical company developing innovative cell therapy platforms for cancer, is pleased to acknowledge and congratulate Professor Alexander Deiters, on receiving the University of Pittsburgh's 2024 Chancellor's Distinguished Research Award.
  • This prestigious award honors outstanding individuals whose scholarly commitments and contributions to research have significantly advanced their respective fields.
  • Deiters' peers described him as "one of the most productive research contributors in the field" whose research program "shows both breadth and depth."
  • "We commend Deiters for his outstanding dedication and invaluable contributions to the development of SNAP-CAR T technology," said Dave Mehalick, President and CEO of Coeptis Therapeutics.

Solid Biosciences Announces Licensing Agreement with Armatus Bio for the Use of AAV-SLB101, a Proprietary, Muscle-Targeted Capsid, in the Development of an RNAi Therapy to treat FSHD

Retrieved on: 
Thursday, March 7, 2024
Liver, Duchenne, Toxicity, Inflammation, DMD, Facioscapulohumeral muscular dystrophy, DUX4, Solid, FSHD, Capsid, MicroRNA, Oxidative stress, B cell, IND, RNA interference, AAV, Atrophy, Vaccine

The AAV-SLB101 capsid has been shown in preclinical studies to have enhanced biodistribution and improved expression in muscle cells.

Key Points: 
  • The AAV-SLB101 capsid has been shown in preclinical studies to have enhanced biodistribution and improved expression in muscle cells.
  • Under the terms of the agreement, Solid granted Armatus a non-exclusive worldwide license to utilize AAV-SLB101 for treatment of FSHD and will provide Armatus AAV-SLB101 plasmid material, preclinical data characterizing AAV-SLB101, and manufacturing and regulatory know-how to enable development.
  • Armatus will be responsible for the development and commercialization of licensed products incorporating AAV-SLB101.
  • With this license in place, we are eager to advance our optimized ARM-201 construct as the lead candidate toward clinical evaluation.”

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Retrieved on: 
Wednesday, March 6, 2024
Therapy, Distribution, Messenger, MicroRNA, Adenocarcinoma, Asos, Vaccine, RNA, Pharmacokinetics, Dicarboxylic acid, Patient, Oligonucleotide, Congress, IND, RNA interference, Metastasis, Cancer

BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland.

Key Points: 
  • BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that its Chief Scientific Officer, Zdravka Medarova, Ph.D., will present at this year’s RNA Leaders Europe Congress scheduled to take place March 12-14 in Basel, Switzerland.
  • The conference is focused on the development of mRNA, RNAi, ASOs, oligonucleotides, vaccines, microRNAs, genome editing, wider nucleic acids and RNA targets.
  • It is expected that delegates from leading companies in these areas will be in attendance.
  • The presentation will also describe key activities completed in support of TransCode’s planned Phase 1/2 trial for which it plans to file an IND in March 2024.

Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements

Retrieved on: 
Wednesday, March 6, 2024
Engineering, Doctor of Philosophy, CAR7, Research and development, Chromosome, Kite Pharma, CD7, Cell, Risk, MicroRNA, Safety, History, Malignancy, Patient, Development, Partnership, Vaccine

“miCAR7 is the product of thoughtful design and remarkable engineering,” commented Dr. Marco Alessandrini, PhD, Chief Executive Officer of Antion.

Key Points: 
  • “miCAR7 is the product of thoughtful design and remarkable engineering,” commented Dr. Marco Alessandrini, PhD, Chief Executive Officer of Antion.
  • Proof-of-Concept data for miCAR7 was unveiled for the first time at the 7th CAR-TCR Summit in London on February 28th, 2024.
  • In August of 2023, Antion successfully delivered novel gene constructs and a supporting data package for silencing of four relevant targets to Allogene.
  • With a validated technology platform, established operations and a history of fruitful collaboration, Antion is optimally positioned to accelerate its pipeline developments, while leveraging the full potential of its technology through key strategic partnerships with global innovation leaders.

Capricor Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, February 29, 2024
Vaccine, Project, Webcast, Exosome, Protein, Poster, Mouse, Infection, Liver, Bangladesh Technical Education Board, Biotechnology, NIAID, Marketing, File, BLA, Therapy, Congress, PPMD, PUL, WMS, CMC, Distribution, International, Regenerative medicine, ID, Duchenne muscular dystrophy, Safety, Dicarboxylic acid, Biologics license application, IND, Commercialization, SARS-CoV-2, Lipid, Messenger, MicroRNA, Inflammation, FDA, Food, DMD, Priority review, Cell, COVID-19, Report, Patient, Oligonucleotide, PRV, Kidney, Tissue, Pharmaceutical industry

Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.

Key Points: 
  • Further, Capricor will receive a meaningful mid-range double-digit revenue share of product revenue under the terms of this Agreement.
  • Next steps for Cohort A: plan to report top-line data in the fourth quarter of 2024.
  • Revenues for the fourth quarter of 2023 were approximately $12.1 million compared with approximately $1.0 million for the fourth quarter of 2022.
  • Operating expenses: Total operating expenses for the fourth quarter of 2023 were approximately $13.2 million compared with approximately $9.0 million for the fourth quarter of 2022.

GCANRx Announces Completion of Preclinical Study for Neuropsychiatric Cannabinoid Therapy

Retrieved on: 
Tuesday, February 27, 2024
Therapy, Reactive oxygen species, Alzheimer's disease, MicroRNA, Inflammation, OTC, LPS, Schizophrenia, Nitric oxide, Cell, Factorization of polynomials, Safety, Protein, Clinical trial, Gene, DSM-IV codes, ROS, Hebrew University of Jerusalem, Microglia, Anoxic waters, Spectrum, Al-Quds, Research, Cannabidiol, Pharmaceutical industry

Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.

Key Points: 
  • Professor Tal Burstyn-Cohen, Ph.D. of the Hebrew University, through the Yissum Research Development Company, led the preclinical study.
  • The preclinical study aimed to assess the impact of various combinations of the neuroprotective therapeutic in a preclinical model.
  • “We are excited to finally receive the positive results from our preclinical study, which was our first step in validating our novel, cannabinoid based therapeutic,” said Aitan Zacharin, GCANRx CEO.
  • To receive the latest information about GCANRx sign up to the investor email at https://bit.ly/2ZNlBoj or follow @GCANRX on Twitter.

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research

Retrieved on: 
Tuesday, February 20, 2024
BBB, Traffic barrier, Messenger, Voyager, Conference, MicroRNA, RNA, Therapy, Pharmacokinetics, Patient, Cognition, VY, IND, AAV, DSM-IV codes, PET, Mouse, Brain, Vaccine

LEXINGTON, Mass., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company dedicated to advancing neurogenetic medicines, today announced new data from its two preclinical programs targeting pathological tau for the treatment of Alzheimer’s disease. Data on VY-TAU01, Voyager’s lead anti-tau antibody candidate, and on Voyager’s tau silencing gene therapy program will be presented at the upcoming 2024 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders (AD/PD™ 2024), taking place March 5-9, 2024, in Lisbon, Portugal.

Key Points: 
  • Tau Silencing Gene Therapy Program:
    Intravenous administration of BBB-penetrant AAV containing primary artificial microRNA targeting tau reduces tau broadly and robustly in hTau mouse brain.
  • Voyager’s tau silencing gene therapy program combines vectorized tau-targeted siRNA with a proprietary, blood-brain barrier (BBB)-penetrant capsid derived from the Company’s TRACER™ discovery platform.
  • Based on these data, Voyager has advanced this program into late research and expects to file an investigational new drug (IND) application in 2026.
  • Pharmacokinetics and tolerability of VY-TAU01, an anti-tau antibody for the treatment of Alzheimer’s disease, in P301S mouse and nonhuman primate.